SELDI‐TOF MS analysis of the Cardiac Troponin I forms present in plasma from patients with myocardial infarction

The troponin (Tn) complex is composed of troponin T, troponin C and troponin I. The cardiac isoform of TnI (cTnI) is modified and released in blood of patients with cardiovascular diseases as a heterogeneous mixture of free, complexed and posttranslationally modified forms. With the aim to determine later, whether specific forms of cTnI could be associated with the different pathologies leading to cTnI release, the cTnI forms present in the plasma from 64 patients with acute myocardial infarction (AMI) have been analysed by SELDI‐TOF MS using anti‐TnI mAbs coupled to PS20 ProteinChips® arrays. Upfront immunoaffinity enrichment using anti‐cTnI 19C7 mAb allowed us to detect cTnI and bis‐phosphorylated cTnI in 11/12 and 9/12 analyses respectively, as well as truncated cTnI in plasma with concentration of cTnI as low as 8 ng/mL. Cardiac troponin C (cTnC) and covalent TnIC complex were also found in pools of plasma with higher concentrations of cTnI. MAb 19C7‐affinity SELDI‐TOF MS analysis performed after immunopurification of one pool of AMI plasma with anti‐free cTnI, anti‐cTnC, and anti‐phosphorylated cTnI mAbs indicated that intact and bis‐phosphorylated cTnI were mostly under the free form. Besides, a 18 718 m/z peak could correspond to a truncated phosphorylated form initially complexed with cTnC.

[1]  R. Hodges,et al.  Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. , 1998, Circulation research.

[2]  N. Morjana,et al.  Biochemical and immunological properties of human cardiac troponin I fragments , 2001, Biotechnology and applied biochemistry.

[3]  N. Morjana.  Degradation of human cardiac troponin I after myocardial infarction , 1998, Biotechnology and applied biochemistry.

[4]  J. Potter,et al.  Phosphorylation of Both Serine Residues in Cardiac Troponin I Is Required to Decrease the Ca2+ Affinity of Cardiac Troponin C (*) , 1995, The Journal of Biological Chemistry.

[5]  S. Weinberger,et al.  Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.

[6]  A. Wu,et al.  Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI Standardization. , 1998, Clinical chemistry.

[7]  M. Deeg,et al.  Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients , 2004, Laboratory Investigation.

[8]  E. Petricoin,et al.  SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. , 2004, Current opinion in biotechnology.

[9]  J. V. Van Eyk,et al.  Developing the next generation of cardiac markers: disease-induced modifications of troponin I. , 2004, Progress in cardiovascular diseases.

[10]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[11]  K. Pulkki,et al.  Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. , 1997, Clinical chemistry.

[12]  G. Thomas,et al.  Diagnostic potential of phosphorylated cardiac troponin I as a sensitive, cardiac-specific marker for early acute coronary syndrome: preliminary report. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[13]  George L. Wright,et al.  SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. , 2002, Expert review of molecular diagnostics.

[14]  J. V. Van Eyk,et al.  Strategy for analysis of cardiac troponins in biological samples with a combination of affinity chromatography and mass spectrometry. , 2003, Clinical chemistry.

[15]  S. Schiaffino,et al.  Specific degradation of troponin T and I by mu-calpain and its modulation by substrate phosphorylation. , 1995, The Biochemical journal.

[16]  E. Fung,et al.  SELDI-TOF-MS proteomics of breast cancer , 2005, Clinical chemistry and laboratory medicine.

[17]  D. Ward,et al.  Structural Consequences of Cardiac Troponin I Phosphorylation* , 2002, The Journal of Biological Chemistry.

[18]  D. Ward,et al.  NMR and mutagenesis studies on the phosphorylation region of human cardiac troponin I. , 2004, Biochemistry.

[19]  G. Deléage,et al.  Anti-free prostate-specific antigen monoclonal antibody epitopes defined by mimotopes and molecular modeling. , 1999, Clinical chemistry.

[20]  B. Sykes,et al.  Phosphorylation and mutation of human cardiac troponin I deferentially destabilize the interaction of the functional regions of troponin I with troponin C. , 2003, Biochemistry.

[21]  S. Perry,et al.  The ordered phosphorylation of cardiac troponin I by the cAMP-dependent protein kinase--structural consequences and functional implications. , 1997, European journal of biochemistry.

[22]  L. Voipio‐Pulkki,et al.  Degradation of cardiac troponin I: implication for reliable immunodetection. , 1998, Clinical chemistry.

[23]  R. Hodges,et al.  Mapping of a second actin-tropomyosin and a second troponin C binding site within the C terminus of troponin I, and their importance in the Ca2+-dependent regulation of muscle contraction. , 1997, Journal of molecular biology.

[24]  M. Welch,et al.  Heterogeneity in human cardiac troponin I standards. , 2000, Analytical biochemistry.

[25]  D. K. Arrell,et al.  Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. , 1999, Circulation research.

[26]  P. Lewczuk,et al.  Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease , 2004, Biological Psychiatry.

[27]  William E Grizzle,et al.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  R. Valdes,et al.  Application of bioaffinity mass spectrometry for analysis of ligands. , 2005, Therapeutic drug monitoring.

[29]  D. Bhandari,et al.  The effects of phosphorylation of cardiac troponin-I on its interactions with actin and cardiac troponin-C. , 1995, European journal of biochemistry.

[30]  R. Caprioli,et al.  Modulation of cardiac troponin C-cardiac troponin I regulatory interactions by the amino-terminus of cardiac troponin I. , 2001, Biochemistry.

[31]  W. Wodzig,et al.  Protein profiling as a diagnostic tool in clinical chemistry: a review , 2005, Clinical chemistry and laboratory medicine.

[32]  E. Braunwald,et al.  Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.

[33]  Robert C. Payne,et al.  Extensive Troponin I and T Modification Detected in Serum From Patients With Acute Myocardial Infarction , 2000 .

[34]  M. Zhang,et al.  Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays. , 1999, Clinical chemistry.

[35]  G. Deléage,et al.  Selective recognition of enzymatically active prostate‐specific antigen (PSA) by anti‐PSA monoclonal antibodies , 2005, Journal of molecular recognition : JMR.

[36]  L. Wallentin,et al.  Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). , 2002, The American journal of cardiology.

[37]  David M Bunk,et al.  Characterization of a new certified reference material for human cardiac troponin I. , 2006, Clinical chemistry.

[38]  D. Atar,et al.  Cardiac Troponin I Is Modified in the Myocardium of Bypass Patients , 2001, Circulation.

[39]  D. Atar,et al.  Role of troponin I proteolysis in the pathogenesis of stunned myocardium. , 1997, Circulation research.

[40]  N. Anderson,et al.  Multi‐component immunoaffinity subtraction chromatography: An innovative step towards a comprehensive survey of the human plasma proteome , 2003, Proteomics.

[41]  J. V. Van Eyk,et al.  C-Terminal Truncation of Cardiac Troponin I Causes Divergent Effects on ATPase and Force: Implications for the Pathophysiology of Myocardial Stunning , 2003, Circulation research.

[42]  William S Hancock,et al.  A study of glycoproteins in human serum and plasma reference standards (HUPO) using multilectin affinity chromatography coupled with RPLC‐MS/MS , 2005, Proteomics.

[43]  B. Cummins,et al.  Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. , 1987, American heart journal.